Envarsus in Delayed Graft Function (E-DGF) (NCT03864926) | Clinical Trial Compass
CompletedPhase 4
Envarsus in Delayed Graft Function (E-DGF)
United States100 participantsStarted 2019-03-18
Plain-language summary
Envarsus XR is an extended release tacrolimus designed to deliver tacrolimus more consistently, thus avoiding large fluctuations of tacrolimus trough levels with Envarsus XR compared to immediate release tacrolimus. It is expected that patients with DGF on Envarsus XR will have more stable tacrolimus levels and facilitate early recover from DGF compared to immediate release tacrolimus.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Willing and able to provide written informed consent
✓. Willing to comply with all study procedures and be available for the duration of the study
✓. Male or female, at least 18 years of age
✓. Documented diagnosis of DGF or need for dialysis or had dialysis within the first week of kidney transplant
✓. Current treatment with tacrolimus based regimen or planned to start tacrolimus based immunosuppressive regimen
✓. Females of childbearing potential must have a negative urine or serum pregnancy test prior to randomization and agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to randomization, for the duration of study participation, and for 7 days following completion of therapy.
Exclusion criteria
✕. History of hypersensitivity or allergy to any of the study drugs or drugs of similar chemical classes
✕. Current use of non-tacrolimus based immunosuppressive regimen or no plan to start tacrolimus based regimen
✕. Women who are or plan to become pregnant or breast-feeding during the study period
✕. Not suitable for study participation due to other reasons at the discretion of the investigator
✕. Major post-surgical complications requiring allograft nephrectomy
What they're measuring
1
Number of Days Needed to Recover From Delayed Graft Function (DGF)